This is a working overview of counterion, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-16 and is reviewed periodically as new material appears.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
Semax is supplied as a lyophilized powder that appears white to off-white. It dissolves readily in water, phosphate-buffered saline, and other aqueous media, which simplifies preparation of working solutions for laboratory use. The nasal products registered in Russia are dilute aqueous solutions, typically around 0.1 percent peptide by weight. Organic solvents are rarely necessary and can complicate handling. Because the peptide is hygroscopic, weighing should be performed quickly and with minimal exposure to ambient humidity.
Solid material is normally kept at minus 20 degrees Celsius in a sealed, desiccated container. Reconstituted solutions are less stable and are usually divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of activity. Light exposure is minimized by using amber glassware or foil wrapping. Published stability data for this peptide are sparse, so recommended storage conditions rest mainly on general practice for short synthetic peptides rather than on dedicated study.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, with ultraviolet detection near 214 nanometers for the peptide backbone. Mass spectrometry, either electrospray or matrix-assisted laser desorption, confirms molecular mass and detects truncation or modification products. Amino acid analysis can verify composition. Because the sequence contains no strongly absorbing aromatic residue apart from phenylalanine, detection wavelengths are chosen carefully. Purity values above 95 percent are typical for research-grade material.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Calculated for the free peptide |
| Molar mass | 813.9 g/mol | Anhydrous free base |
| Peptide class | Synthetic heptapeptide | ACTH(4-10) analogue |
| Parent fragment | ACTH(4-10) | Adrenocorticotropic hormone segment |
| Developmental origin | Institute of Molecular Genetics, Moscow | Work began in the 1980s |
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
=== Legal status === As of 2021, phenibut is a controlled substance in Australia, France, Hungary, Italy, Lithuania, and Germany where, nevertheless, it is readily obtained online. In 2015, it was suggested that the legal status of phenibut in Europe should be reconsidered due to its recreational potential. In February 2018, the Australian Therapeutic Goods Administration declared it a prohibited (schedule 9) substance, citing health concerns due to withdrawal and overdose. As of 14 November 2018, Hungary added phenibut and 10 other items to its New Psychoactive Substances ban list, and, as of 26 August 2020, Italy added phenibut to its New Psychoactive Substances ban list. As of 18 September 2020, France added phenibut to the controlled psychoactive substances list, prohibiting production, sale, storage, and use. In the United States, phenibut is an unapproved drug, but is often misleadingly marketed as a dietary supplement. It is readily available without a prescription. In Alabama, phenibut was made a Schedule II substance at the state level in November 2021.
It has been the world's largest producer of coffee for the last 150 years and is the world's largest producer of sugarcane, soy, coffee and oranges; is one of the top five producers of maize, cotton, lemon, tobacco, pineapple, banana, beans, coconut, watermelon and papaya; and is one of the top 10 world producers of cocoa, cashew, mango, rice, tomato, sorghum, tangerine, avocado, persimmon, and guava, among others. Regarding livestock, it is one of the five largest producers of chicken meat, beef, pork and cow's milk in the world. In the mining sector, Brazil is among the largest producers of iron ore, copper, gold, bauxite, manganese, tin, niobium, and nickel. In terms of precious stones, Brazil is the world's largest producer of amethyst, topaz, agate and one of the main producers of tourmaline, emerald, aquamarine, garnet and opal. The country is a major exporter of soy, iron ore, pulp (cellulose), maize, beef, chicken meat, soybean meal, sugar, coffee, tobacco, cotton, orange juice, footwear, airplanes, cars, vehicle parts, gold, ethanol and semi-finished iron, among other products. Brazil is the world's 24th-largest exporter and 26th-largest importer as of 2021. China is its largest trading partner, accounting for 32% of the total trade. Other large trading partners include the United States, Argentina, the Netherlands and Canada. Its automotive industry is the eighth-largest in the world. In the food industry, Brazil was the second-largest exporter of processed foods in the world in 2019.
== External links == Top words from 2000 – present @ Global Language Monitor Word of the Year Archive @ Macquarie Dictionary Word of the Year Archive @ Merriam-Webster Word of the Year Archive @ OxfordWords blog Austrian Word of the Year Canadian Word of the Year Liechtenstein Word of the Year Switzerland Word of the Year Dictionary.com word of the year @ Dictionary.com
==== GnRH-associated peptide ==== GnRH-associated peptide (GAP), a 56-amino-acid peptide cleaved from the GnRH precursor, was shown in 1985 to inhibit prolactin secretion in rat pituitary cultures at a potency comparable to dopamine. Its physiological significance in vivo remains uncertain, as results have varied across species.
=== Legal status === In August 2026, Scholar Rock Netherlands withdrew its application for a marketing authorization of Isembyld for the treatment of 5q spinal muscular atrophy. The company stated that the manufacturing site used to make the medicine had not demonstrated compliance with EU GMP requirements within the required time limit. Apitegromab was authorized for medical use in the United States in September 2026. The US Food and Drug Administration (FDA) granted the application for apitegromab fast track, orphan drug, and rare pediatric disease designations. The FDA granted the approval of Isembyld to Scholar Rock.
Sources: en.wikipedia.org
== Invertebrate skeletons == Invertebrates are defined by a lack of vertebral column, and they do not have bone skeletons. Arthropods have exoskeletons and echinoderms have endoskeletons. Some soft-bodied organisms, such as jellyfish and earthworms, have hydrostatic skeletons.
The study of the effect of infectious agents on metabolism is still in its early stages. Gut flora has been shown to differ between lean and obese people. There is an indication that gut flora can affect the metabolic potential. This apparent alteration is believed to confer a greater capacity to harvest energy contributing to obesity. Whether these differences are the direct cause or the result of obesity has yet to be determined unequivocally. The use of antibiotics among children has also been associated with obesity later in life. An association between viruses and obesity has been found in humans and several different animal species. The amount that these associations may have contributed to the rising rate of obesity is yet to be determined.
In 1985, the FDA further required a boxed warning to be added, but the problem grew with an estimated 1000 birth defects attributed to the drug by early 1988. While an advisory committee of pediatricians and Centers for Disease Control and Prevention (CDC) staff advised the FDA to restrict Accutane prescriptions, the FDA instead required Roche to expand its warnings of potential side effects and provide informed consent forms to doctors. In 2000, the CDC reported that Roche's Pregnancy Prevention Program of providing contraception counseling and pregnancy testing for women prescribed Accutane was ineffective. The revamped "Targeted Pregnancy Prevention Program" advised women to use two kinds of contraceptives and two pregnancy tests while requiring doctors to directly provide prescriptions to pharmacists to limit off-label use. After Representative Bart Stupak's son committed suicide while taking Accutane in May 2000, Congress held hearings in which some dermatologists attested to Accutane's efficacy in reducing acne and its associated stigma, while others petitioned the FDA for further restrictions of its use. In 2001, the FDA announced the System to Manage Accutane Related Teratogenicity (SMART), which required Roche to train doctors for a sticker-based system of verifying that female patients took pregnancy tests before using Accutane. SMART was replaced by the iPLEDGE program in March 2006. In February 2002, Roche's patents for isotretinoin expired, allowing generic drugs to enter the market.
== Causes == Myxedema is known to occur in various forms of hypothyroidism, as well as hyperthyroidism, including Graves' disease. One of the hallmarks of Graves' disease is pretibial myxedema, myxedema of the lower limb. Myxedema is more common in women than in men. Myxedema can occur in:
Sources: en.wikipedia.org
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.
It is registered for clinical use in Russia and a few other countries, typically as a nasal drop formulation. It does not hold approval from the United States Food and Drug Administration or the European Medicines Agency. Outside those markets it is generally handled as a research chemical.
The compound was developed in Moscow and the earliest studies were conducted there, so the primary literature is largely in Russian-language journals. Translation and indexing have been incomplete, which limits access for outside researchers. Independent groups have since published some work, but the total volume remains modest.
Solid peptide is best kept frozen at about minus 20 degrees Celsius in a sealed container with desiccant. It should be allowed to reach room temperature before opening to prevent condensation. Repeated warming and cooling of the same vial is discouraged.